Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, is a pandemic causing havoc globally. Currently, there are no Food and Drug Administration (FDA)-approved drugs to treat COVID-19. Off-label drug use, in lieu of evidence from published randomized, double-blind, placebo-controlled clinical trials, is common in COVID-19. Although it is vital to treat affected patients with antiviral drugs, there is a knowledge gap regarding the use of anti-inflammatory drugs in these patients.

One critical question is which anti-inflammatory drugs are most appropriate. At present, there is insufficient clinical data to recommend either for or against the use of chloroquine, hydroxychloroquine, convalescent plasma, hyperimmune immunoglobulin, interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab), interleukin-1 inhibitors (e.g., anakinra), except in the context of a clinical trial (<https://www.idsociety.org/covid19guidelines>; <https://covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/>).

Colchicine, made from preparations of the meadow saffron *Colchicum autumnale*, has been used for over 2000 years as a poison and as a remedy for gout flares \[[@CR1]\]. However, the full configuration of colchicine was determined only in 1955 when it was identified as a neutral lipophilic tricyclic alkaloid, the main features of which include a trimethoxyphenyl ring, a 7-membered ring with an acetamide at the seven position, and a tropolonic ring \[[@CR2]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Colchicine is anti-inflammatory

Colchicine for oral use (capsule/tablet/liquid) is currently FDA approved for the prevention and treatment of gout flares in adults with gout and Familial Mediterranean fever (FMF) (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information>). Off-label uses for colchicine are many and include acute calcium pyrophosphate (CPP) arthritis (pseudogout), sarcoid and psoriatic arthritis, Behcet's disease, and pericarditis, and recently, studies have shown colchicine's efficacy in preventing major cardiovascular adverse events among patients who suffered a recent myocardial infarction \[[@CR3]\].

Despite over 2000 years of use, new therapeutic uses of colchicine, beyond gout \[[@CR4]\], are being explored. Colchicine trials to combat inflammation in COVID-19 patients have not received much attention. Currently, ten colchicine clinical trials are in progress for the treatment of SARS-CoV-2 infection and are listed in [clinicaltrials.gov](http://clinicaltrials.gov) (<https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=>) (Table [1](#Tab1){ref-type="table"}).Table 1Registered clinical trials investigating colchicine in COVID-19 infectionStudyDesignCountryTarget enrollmentColchicine doseSettingPrimary outcomeCOLHEART-19/NCT04355143Randomized, open label clinical trialUnited Stated1500.6 mg every 12 h for 30 daysInpatientMaximum troponin levelCOLCOVID/NCT04328480Randomized, open label clinical trialArgentina2500In patients not receiving lopinavir/ritonavir, loading dose of 1.5 mg followed by 0.5 mg after 2 h (day 1); then next day 0.5 mg bid for 14 days or until discharge.In patients receiving lopinavir/ritonavir, loading dose of 0.5 mg (day 1); after 72 h from the loading dose, 0.5 mg every 72 h for 14 days or until discharge.In patients under treatment with colchicine that are starting with lopinavir/ritonavir; dose of 0.5 mg 72 h after starting lopinavir/ritonavir; continue with 0.5 mg every 72 h for 14 days or until discharge.InpatientAll-cause mortalityNCT04360980Randomized, double-blind clinical trialIran801.5 mg loading dose then 0.5 mg twice dailyInpatientC-reactive protein × neutrophil-to-lymphocyte ratio changeCOL-COVID/NCT04350320Randomized, open label clinical trialSpain102Initial dose of 1.5 mg (1 mg and 0.5 mg 2 h after), followed by 0.5 mg every 12 h during the next 7 days and 0.5 mg every 24 h until the completion of 28 days of total treatmentIn patients receiving ritonavir or lopinavir or with reduced renal clearance (\< 50 ml/min/1.37m^2^), weight \< 70 kg or age \> 75 years old, the dose will be adjusted to the halfInpatientChanges in the patients' clinical status through the 7 points ordinal scaleCOLCORONA/NCT04322682Randomized, placebo-controlled clinical trialCanadaSpainUnited States60000.5 mg twice daily for the first 3 days and then once daily for the last 27 daysOutpatientNumber of participants who die or require hospitalization due to COVID-19 infectionColchiVID/NCT04367168Randomized, placebo-controlled, double blind clinical trialMexico1741.5 mg at day 1 followed by 0.5 mg PO twice daily to complete 10 days of treatmentInpatientNumber of patients with improvement in body temperature, myalgia, arthralgia, total lymphocyte count, D-dimer, fibrinogen and ferritin levelsColCOVID-19/NCT04322565Randomized, open label clinical trialItaly3101 mg (or 0.5 mg in chronic kidney disease) per dayInpatientTime to clinical improvement defined as time from randomization to an improvement of two points from the status at randomization on a seven-category ordinary scaleCOMBATCOVID19/NCT04363437Randomized, open label clinical trialUnited States70Starting dose of 1.2 mg followed, by 0.6 mg after 2 h if they do not have significant gastrointestinal symptoms, on day 1. Then, 0.6 mg twice a day for 14 days or until discharged or release from the hospitalInpatientPercentage of Patients requiring supplemental oxygen beyond 8 l nasal cannulaGRECCO-19/NCT04326790Randomized, open label clinical trialGreece1800.5 mg twice dailyN/AClinical deterioration in the semi-quantitative ordinal scaleCOLVID-19/NCT04375202Randomized, open label clinical trialItaly3080.5 mg three times a day if weight is less than 100 kg; 1 mg twice a day if weight is more than 100 kg for 30 days or up to dischargeInpatientComposite of respiratory failure requiring mechanical ventilation; organ failure requiring ICU monitoring and treatment; death

This review gives a spotlight on colchicine's anti-inflammatory and antiviral properties and why colchicine may help fight COVID-19. This review summarizes colchicine's mechanism of action via the tubulin-colchicine complex. Furthermore, it discussed how colchicine interferes with several inflammatory pathways, including inhibition of neutrophil chemotaxis, adhesion, and mobilization; disruption of superoxide production, inflammasome inhibition, and tumor necrosis factor reduction; and its possible antiviral properties. In addition, colchicine dosing and pharmacokinetics, as well as drug interactions and how they relate to ongoing, colchicine in COVID-19 clinical trials, are examined.

Colchicine's Mechanism of Action {#Sec2}
================================

Tubulin-Colchicine Complex {#Sec3}
--------------------------

Colchicine is an inhibitor of mitosis and microtubule assembly. It binds to soluble, non-polymerized tubulin heterodimers to form a tight tubulin-colchicine complex \[[@CR5]\]. At lower doses, colchicine interferes with microtubule formation and elongation, and at higher doses, colchicine promotes microtubule depolymerization \[[@CR6]\] (Fig. [1](#Fig1){ref-type="fig"}). Furthermore, the polymerization of colchicine-bound tubulin occurs in a manner closely related to microtubule assembly, resulting in a polymer with different morphology, causing a distortion in normal tubulin polymerization and microtubule generation \[[@CR7]\]. Since microtubules are involved in a variety of cellular processes, such as cell division, maintenance of cell shape, cell signaling, signal transduction, cell migration, and cellular transport, colchicine can inhibit these functions as well as neutrophil chemotaxis.

Colchicine binds not only to tubulin but also to leukocyte membrane proteins that often provide sites for attachment of microtubules and consequent cytoskeletal reorganization \[[@CR8]\]. However, most of the anti-inflammatory effects of colchicine are likely due to the disruption of microtubule function; hence, cells with high proliferative rates are disproportionately affected by colchicine \[[@CR5]\]. Furthermore, inhibition of ameboid motility by colchicine prevents disruption of membrane-dependent functions, such as chemotaxis and phagocytosis \[[@CR9]\].

Colchicine Interferes with Several Inflammatory Pathways (Fig. [1](#Fig1){ref-type="fig"}) {#Sec4}
==========================================================================================

The anti-inflammatory effects of colchicine are diverse. Colchicine has an inhibitory effect on neutrophil functions, such as adhesiveness, motility, and degranulation of lysosomes \[[@CR10]\], and neutrophil chemotaxis \[[@CR11]\]. Colchicine decreases the expression of adhesion molecules on neutrophil membranes, leading to a significant inhibition in migration and interaction with endothelial cells and modulates the production of proinflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α.

Inhibition of Neutrophil Chemotaxis, Adhesion, and Mobilization {#Sec5}
---------------------------------------------------------------

The concentration of colchicine that accumulates in neutrophils may be more than 16 times the peak concentration observed in plasma \[[@CR12]\]. This observation may be due to little or no expression of P-glycoprotein (P-gp), an integral membrane, and adenosine triphosphatase (ATPase) efflux protein in neutrophils \[[@CR13]\]. P-gp facilitates the removal of colchicine from cells. Thus, a relative lack of P-gp may allow colchicine to accumulate in neutrophils, helping to explain how colchicine seems to target neutrophils selectively.

In many inflammatory diseases, neutrophils are the primary cells involved in the immune response. The first step in the pathogenesis of inflammation is the adhesion of neutrophils to endothelial cells \[[@CR14]\]. Their participation in inflammation depends upon their ability to migrate towards damaged or stimulated tissue \[[@CR15]\]. Since neutrophil migration is dependent on microtubules, colchicine binding to tubulin distorts this capability, thereby suppressing the inflammatory process. Colchicine dramatically reduces the adhesion of neutrophils to the endothelium. Endothelial cells play a vital role in neutrophil transmigration towards the inflammatory site, and colchicine inhibits stimulation-mediated endothelial adhesiveness via its effects on microtubules. Colchicine interferes with neutrophil-endothelial interactions by altering the number and/or distribution of selectins on endothelial cells and neutrophils and decreases E-selectin-mediated adhesiveness of the cytokine-stimulated vascular endothelium to neutrophils at nano-α-prophylaxis \[[@CR16]\]. At higher micro-concentrations (IC50 = 300 nM), colchicine induces the shedding of neutrophil adhesion molecules. In addition, colchicine disrupts microtubule structure and reduces neutrophil elasticity and relaxation, thus preventing neutrophil extravasation from the blood vessels to the site of inflammation. This disruption may be the last and most effective step in inhibiting chemotaxis \[[@CR17]\].

Disruption of Superoxide Production {#Sec6}
-----------------------------------

In the presence of colchicine, peritoneal mouse macrophages show less adenosine triphosphate (ATP)-induced permeability to ethidium bromide and decreased formation of reactive oxygen species (ROS), nitric oxide (NO), and release of IL-1β. Colchicine inhibits monosodium urate (MSU)-induced superoxide production by murine peritoneal macrophages in vivo at doses 100 times lower than that required to inhibit neutrophil infiltration \[[@CR18]\], suggesting that superoxide anion production may be more sensitive to suppression by colchicine than microtubule formation involved in cell migration. The production of ROS may act as a common event upstream of the NACHT-LRRPYD-containing protein 3 (NLRP3) inflammasome \[[@CR19]\], a signaling pathway described below. TNF is a regulator of the generation of ROS, and TNF-α and ROS influence each other in a positive feedback loop.

Inflammasome Inhibition {#Sec7}
-----------------------

A major signaling pathway of the innate immune system is the inflammasome, a multiprotein complex, primarily expressed in monocytes and macrophages, with little expression in other leukocytes or adipocytes \[[@CR20], [@CR21]\]. The NLRP3 inflammasome is composed of three distinctive components: NLRP3, an apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1. Activation of NLRP3 leads to the production of active IL-1β and IL-18. The colchicine-tubulin complex blocks NLRP3 inflammasome formation and activation by inhibiting microtubule polymerization and attenuates macrophage NLRP3 inflammasome arrangement and activation in vitro and in vivo \[[@CR22], [@CR23]\]. This attenuation stems from disruption of microtubule-mediated transport of mitochondria (where endogenous ASC is localized) to the endoplasmic reticulum, where NLRP3 is localized. The co-localization of NLRP3 and ASC is required for assembly and activation of the inflammasome to produce mature IL-1β.

While plasma concentration after a single dose of 0.6 mg colchicine is approximately 3 nmol/L, neutrophils can contain levels of 40--200 nmol/L \[[@CR24]\]. Although many of the experiments performed in vitro have used larger doses not feasible for use in humans, a standard low dose of colchicine drastically reduces serum levels of inflammasome products and caspase-1 monocyte production \[[@CR25]\]. In a mouse myocardial infarct model, at doses equivalent to those used in humans (0.1 mg/kg), colchicine reduces the expression of NLRP3 inflammasome components in addition to lowering inflammatory mediators \[[@CR26], [@CR27]\].

Tumor Necrosis Factor Reduction {#Sec8}
-------------------------------

Colchicine reduces both the generation of TNF-α by macrophages and its receptors on endothelial cells \[[@CR28], [@CR29]\]. Colchicine modulates lipopolysaccharide-induced secretion of TNF-α by liver macrophages in a rat model and down-regulates TNF-α receptors on endothelial cells by 70--75%, resulting in diminished surface expression \[[@CR28]\]. Importantly, TNF-α induces nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and the stability of microtubules correlates with the regulation of NF-κB signaling. Specifically, if microtubules are destabilized by colchicine, the induction of NF-κB by TNF-α is significantly reduced \[[@CR29]\].

Anti-viral Properties of Colchicine {#Sec9}
===================================

Tubulin ligands have the potential to inhibit the replication of viruses that depend on the microtubule network. The intracellular transport of viral particles in the host cell, including particle trafficking in later stages of the infection, is mediated by microtubules and associated proteins \[[@CR30], [@CR31]\]. By inhibiting microtubule polymerization, colchicine has been reported to cause a significant decrease in virus replication in flaviviruses, such as dengue and Zika viruses \[[@CR32]\]; blocks transport and reduces the replication of recombinant demyelinating strain of the mouse hepatitis virus \[[@CR33]\]; inhibits respiratory syncytial virus (RSV) infection in neonatal rats through regulation of anti-oxidative factor production leading to inhibition of RSV replication, thus, leading to a significant reduction in the levels of IL-6 and TNF-α \[[@CR34]\]. In addition, colchicine and colchicine derivatives may influence HIV viral load \[[@CR35]\].

Coronaviruses, members of the Nidovirales order, are enveloped, positive-sense, single-stranded RNA viruses, which redirect and rearrange host cell membranes for use as part of the viral genome replication and transcription \[[@CR35]\]. Their replication moves in the cell in a manner that corresponds to microtubule-associated transport, inducing the formation of double-membrane vesicles in infected cells \[[@CR36]\]. The infection of cells by coronaviruses involves the interaction of the cytoplasmic tail of the spike protein with cytoskeletal proteins (i.e., tubulin) \[[@CR37]\]. This interaction leads to viral entry. Furthermore, microtubules are involved in the transport and assembly of spike proteins into virions during the replication cycle \[[@CR38], [@CR39]\]. The colchicine-tubulin complex may block viral entry and replication \[[@CR40]\]. This hypophysis requires confirmation.

In an animal model of bronchopulmonary dysplasia, colchicine-treated rat pups had decreased lung damage and lower lung concentrations of IL-1 and TNF-α, suggesting that this therapeutic will reach the target tissue in COVID-19 \[[@CR41]\]. Furthermore, other organs are affected by COVID-19-related inflammation, including the myocytes. Previous studies demonstrate the anti-inflammatory activity of colchicine on the heart \[[@CR3], [@CR42]\]. It has been suggested that SARS-CoV and its accessory protein are potent activators of pro-IL-1β gene transcription and protein maturation, and thus, can activate the NLRP3 inflammasome. Influenza virus M2 or encephalomyocarditis virus (EMCV) 2B proteins 2B protein stimulate IL-1β secretion following activation of the NLRP3 inflammasome \[[@CR43]\]. Importantly, in experimental models of acute respiratory distress syndrome/acute lung injury (ARDS/ALI), the NLRP3 inflammasome plays a significant role in the development of lung injury \[[@CR44]\].

In a case report of a COVID-19-infected patient with signs of systemic inflammation, treatment with 1 mg of colchicine on day 8 and 0.5 mg/day after that was reported to be beneficial \[[@CR45]\].

Pharmacokinetics {#Sec10}
================

Colchicine is absorbed in the jejunum and ileum and accumulates in tissues. It is metabolized in the liver and the intestine by cytochrome P (CYP) 450 3A4 and P-glycoprotein (P-gp). The absorption of oral colchicine is rapid but incomplete (time to max = 2 h; bioavailability = 25--50%). However, absorption can be highly variable. The onset of action is approximately 24 h via the oral route. The half-life of colchicine after an oral dose in patients with normal renal and hepatic functions is 9 h, whereas, in patients with renal failure, it is 2--3 times the normal length (about 24 h). In cirrhotic patients with renal failure, the half-life is 10 times normal (approximately 4 days) \[[@CR8], [@CR9]\]. Colchicine is not removed by conventional hemodialysis and does not penetrate brain tissue, heart muscle, or skeletal muscle.

Cells in different stages of mitosis exhibit distinct sensitivity to colchicine. At a concentration of 50 nM, colchicine blocks almost all mitotic cells. A distinctive feature of colchicine is its capacity to accumulate in inflammatory cells, reaching higher concentrations than plasma levels and with markedly longer duration of action \[[@CR19], [@CR24]\]. Colchicine is excreted mainly by the biliary system, intestines, and kidneys. The main metabolic pathway for colchicine is deacetylation in the liver, followed by shuttling to enterohepatic circulation before being excreted into the bile (10 to 25%) and the feces (10 to 56% after oral administration) \[[@CR5]\]. Urinary excretion is approximately 10 to 20% of the administered dose. It has been observed that colchicine is still present in the urine as late as 10 days after the administration of a single subtherapeutic dose \[[@CR22]\].

In the presence of mild to moderate renal or hepatic impairment, adjustment of dosing is not required, but patients should be monitored closely. In patients with severe renal or hepatic impairment, chronic gout flare prevention or chronic treatment of FMF, the starting dose should be 0.3 mg/day. For patients undergoing dialysis, the total recommended dose for gout flare prevention is 0.3 mg given twice weekly with close monitoring (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information>).

Dosing in the Ongoing Clinical Trials {#Sec11}
=====================================

Colchicine can be administered by mouth as 0.5 or 0.6 mg and up to 1 mg in tablets. In 2014, the FDA withdrew approval following several cases of fatal toxicity \[[@CR46]\]. For the treatment of gout flares, the FDA-approved dose is 1.2 mg (two tablets) at the first sign of a gout flare followed by 0.6 mg (one tablet) 1 h later (total 1.8 mg). For gout flare prevention, the FDA-approved dose is 0.6 mg once or twice daily with a maximum dose of 1.2 mg/day. For Familial Mediterranean Fever (FMF), the dose is up to 1.2--2.4 mg (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information>).

The oral colchicine dose used in the COVID-19 clinical trials registered on the [clinicaltrialsl.gov](http://clinicaltrialsl.gov) site varies (<https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=>): 0.5 mg twice daily for the first 3 days and then once daily for the last 27 days; 0.6 mg by mouth twice daily for 30 days; 0.5 mg twice daily with no time limit; or 1 mg daily for 30 days. Others use a loading dose of 1.2 mg followed by 0.6 mg after 2 h on day 1 (similar to gout flare treatment) followed by 0.6 mg twice a day for 14 days or until discharged or release from the hospital. Yet, others load with 1.5 mg (1 mg and 0.5 mg 2 h after), followed by 0.5 mg every 12 h during the next 7 days and 0.5 mg every 24 h after until the completion of 28 days of total treatment versus two other trials that have the same loading dose of 1.5 mg but follow with a twice-daily dose for 10 days. Yet, another clinical trial has no time limit for the twice-daily dose. Treatment starts in some of these trials as early as the time that a patient tests positive for COVID-19 by a PCR-based assay and others only when patients are experiencing cardiac injury or show evidence of cytokine release syndrome.

Only two of the colchicine clinical trials (<https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=>) mention altering the colchicine dose in patients receiving lopinavir/ritonavir or other conditions placing patients at risk for toxicity (i.e., advanced age, chronic kidney disease), as described below.

Drug Interactions {#Sec12}
=================

As stated above, colchicine is a P-gp and CYP3A4 substrate. The drugs reported causing colchicine toxicity are P-gp inhibitors \[[@CR42]\]. P-gp inhibitors include antacids, such as cimetidine; antibiotics, such as erythromycin and tetracycline; calcium channel blockers, such as diltiazem and verapamil; immunosuppressants, such as cyclosporine and tacrolimus; HIV proteases inhibitors, such as lopinavir and ritonavir; azole antifungals, such as itraconazole and ketoconazole; antiarrhythmic drugs, such as amiodarone, and quinidine; and selective estrogen receptor modulators, such as tamoxifen (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information>). Life-threatening and fatal drug interactions have been reported in patients treated with colchicine given with P-gp and potent CYP3A4 inhibitors \[[@CR42]\]. If treatment with a P-gp or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, the patient's dose of colchicine may need to be reduced or interrupted to prevent toxicity (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information>). Only two of the colchicine clinical trials (<https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=>) address the use of other medications concomitantly with colchicine, which may warrant a decrease in colchicine dosing.

The most common adverse reactions reported in the clinical trial for gout were diarrhea (23%) and pharyngolaryngeal pain (3%). The most common adverse reactions for FMF (up to 20%) are abdominal pain, diarrhea, nausea, and vomiting. These effects are usually mild, transient, and reversible upon lowering the dose (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information>).

Discussion {#Sec13}
==========

The anti-inflammatory effects of colchicine are diverse. Colchicine interferes with several inflammatory pathways, including adhesion and recruitment of neutrophils, superoxide production, inflammasome activation, and TNF-α release. The colchicine-tubulin complex effects microtubules that are essential for SARS-CoV-2 entry, transport, and replication.

The ten colchicine studies currently listed on [clinicaltrials.gov](http://clinicaltrials.gov) (<https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=>) (Table [1](#Tab1){ref-type="table"}) differ in the timing and dosing of colchicine. These are prospective clinical studies to evaluate colchicine efficacy in COVID-19, but they differ in their outcome measures. Some colchicine COVID-19 clinical trials measure lab results, others time to clinical improvement, whereas others measure the efficacy with respect to clinical status assessed by a 7-point ordinal scale recommended by the World Health Organization (<https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf>).

Consistent with the current understanding of colchicine metabolism, certain drugs, such as lopinavir and ritonavir, used as antiviral drugs for the treatment of COVID-19 infection, increase the potential for colchicine toxicity via modulation of P-gp and CYP3A4 activity. However, only two of the colchicine clinical trials address the use of other medications concomitantly with colchicine, which may warrant a decrease in colchicine dosing. These are important observations for those planning colchicine COVID-19 clinical trials.

This review highlights colchicine's anti-inflammatory and antiviral properties and why colchicine may help patients infected with SARS-CoV-2. We await the results of ten ongoing colchicine clinical trials with COVID-19 patients listed on [clinicaltrials.gov](http://clinicaltrials.gov). Large, randomized, multicenter, controlled trials are needed to further evaluate the efficacy as well as optimal colchicine dosing and timing for the treatment of COVID-19.
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